Next Article in Journal
p-Cresol Sulfate Caused Behavior Disorders and Neurodegeneration in Mice with Unilateral Nephrectomy Involving Oxidative Stress and Neuroinflammation
Next Article in Special Issue
Editorial of Special Issue “Genetics and Molecular Pathogenesis of Non-Ischemic Cardiomyopathies”
Previous Article in Journal
Overview of Current Advances in Extrusion Bioprinting for Skin Applications
Previous Article in Special Issue
State of the Art Review on Genetics and Precision Medicine in Arrhythmogenic Cardiomyopathy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 18
10.3390/ijms21186682
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Hidden Fragility in the Heart of the Athletes: A Review of Genetic Biomarkers

by
Ferdinando Barretta
1,2,†,
Bruno Mirra
1,2,†,
Emanuele Monda
3,
Martina Caiazza
3,
Barbara Lombardo
1,2,
Nadia Tinto
1,2,
Olga Scudiero
1,2,
Giulia Frisso
1,2,* and
Cristina Mazzaccara
1,2
1
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy
2
CEINGE Advanced Biotechnologies, 80131 Naples, Italy
3
Department of Translational Medical Sciences, University of Campania ‘Luigi Vanvitelli’, Monaldi Hospital, 80131 Naples, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to the work.
Int. J. Mol. Sci. 2020, 21(18), 6682; https://doi.org/10.3390/ijms21186682
Submission received: 10 July 2020 / Revised: 2 September 2020 / Accepted: 8 September 2020 / Published: 12 September 2020
(This article belongs to the Special Issue Genetics and Molecular Pathogenesis of Non-ischemic Cardiomyopathies)
Browse Figures
Review Reports Versions Notes

Abstract

:
Sudden cardiac death (SCD) is a devastating event which can also affect people in apparent good health, such as young athletes. It is known that intense and continuous exercise along with a genetic background that predisposes a person to the risk of fatal arrhythmias is a trigger for SCD. Therefore, knowledge of the athlete’s genetic conditions underlying the onset of SCD must be extended, in order to develop new effective prevention and/or therapeutic strategies. Arrhythmic features occur across a broad spectrum of cardiac diseases, sometimes presenting with overlapping phenotypes. The genetic basis of arrhythmogenic disorders has been greatly highlighted in the last 30 years, and has shown marked heterogeneity. The advent of next-generation sequencing has constantly updated our understanding of the genetic basis of arrhythmogenic diseases and is laying the foundation for precision medicine. With the exception of a few clinical cases involving a single athlete showing a highly suspected phenotype for the presence of a heart disease, there are few studies to date that analysed the applicability of genetic testing on cohorts of athletes. This evidence shows that genetic testing can contribute to the diagnosis of up to 13% of athletes; however, the presence of clinical markers is essential. This review aims to provide a reference collection on current knowledge of the genetic basis of sudden cardiac death in athletes and to review updated evidence on the effectiveness of genetic testing in early identification of athletes at risk for SCD.

Graphical Abstract

1. Introduction

Sudden cardiac death (SCD) is defined, according to the European Society of Cardiology (ESC), as a non-traumatic, unexpected fatal event occurring within 1 h of the onset of symptoms, in an apparently healthy subject. In about half of cases, SCD occurs after symptoms, such as chest pain, wheezing and shortness of breath, racing heartbeat, palpitations, feeling dizzy or fainting. The term “cardiac” can be used if a potentially fatal cardiac condition, congenital or acquired, was identified or the autopsy showed cardiovascular abnormalities. Therefore, an arrhythmic event is the most probably cause of death [1]. Indeed, arrhythmic episodes, particularly ventricular fibrillation (VF), are the main cause of SCD, and the prevention of VF is a challenge for electrophysiologists, since the risk of VF is considered as a surrogate of the risk of SCD [1,2,3].
Since the end of the last century, numerous studies showed that risk of SCD increases when there is family history of this event, indicating that there may be a genetic predisposition for SCD. [1,4,5,6,7]. Furthermore, data in the literature suggested that SCD may occur as a consequence of a trigger factor in the context of electrical or structural heart disorder (genetic or acquired), which acts as a predisposing condition. Known exogenous triggers resulting in the fatal event of SCD may be fever, alcohol intake, electrolyte disorders, hypertensive crisis, infection, cytotoxic drugs, and pregnancy [8,9,10,11,12,13,14,15,16,17,18]. Moreover, regular physical activity is an important exogenous factor affecting the risk of SCD in predisposed subjects. Physical activity reduces cardiovascular mortality, showing favourable effects on several disorders, i.e., obesity, type 2 diabetes, dyslipidaemias, hypertension (American Heart Association recommendations for physical activity in adults and kids. Available online: https://www.heart.org/en/healthy-living/fitness/fitness-basics/aha-recs-for-physical-activity-in-adults, accessed on 26 August 2020). However, in the presence of cardiovascular conditions predisposing to life-threatening ventricular arrhythmias, vigorous physical activity may transiently increase the risk of SCD, both in males and females, as evidenced by Corrado et al. in adolescents and young adults [19].
SCD is the most frequent medical cause of sudden death in athletes, at any age. However, coronary artery disease is the most frequent cause of SCD in athletes over 35 years of age, while genetic disorders represent an important cause of SCD in young athletes [2,19,20].
The main inherited arrhythmogenic conditions predisposing one to SCD can be grouped into two classes: the primary inherited arrhythmia syndromes, the so called ‘channelopathies’ (i.e., long QT syndrome (LQTS), Brugada syndrome (BrS) and catecholaminergic polymorphic ventricular tachycardia (CPVT)), and the cardiomyopathies (i.e., hypertrophic, dilated and arrhythmogenic cardiomyopathy) [21]. Globally, cardiomyopathies and primary inherited arrhythmia syndromes show a prevalence of 3% in the general population, and represent a major cause of cardiac morbidity and mortality in the young athletes. They are classified as Mendelian diseases, generally caused by variations in a single gene: the mutation is present since birth and the risk of disease may be suspected on the basis of family history and inherited pattern [22]. In the last three decades, thanks to the remarkable progress in the field of molecular genetics, molecular bases of inherited arrhythmia syndromes have been revealed, thus encouraging the investigation of DNA biomarkers for diagnostic purposes. The mechanisms responsible for inherited arrhythmic disorders are multiple. Mutations in exonic regions of genes encoding cardiac ion channels or structural proteins have been associated with different inherited cardiac arrhythmias. However, apparently non-inherited forms of cardiac arrhythmias could be associated with changes in the expression levels of transcript for various proteins. Functional polymorphisms may affect gene transcription, RNA processing, post-transcriptional control of gene expression by miRNA, protein synthesis, assembly and post-translational modification and trafficking, producing a arrhythmic substrates [23].
Actually, in the field of inherited arrhythmogenic syndromes, genetic testing can be used to confirm diagnosis in a clinically affected patient, to reach an early and definitive diagnosis in patients showing overlapping or intermediate phenotypes, and to make a differential diagnosis between genetic and non-genetic forms of disease [22]. Furthermore, genetic tests in the cardiovascular field can also be used for predictive purposes. Indeed, molecular studies carried out in the field of hereditary myocardial diseases unveiled that the reduced penetrance and variable expressivity of genotype generate the so-called asymptomatic or pauci-symptomatic carriers, in which the diagnosis may be unknown or delayed but which may still cause risk of sudden death when exposed to trigger factors, such as the practice of strenuous and continuous sports [22,24]. Finally, genetic testing can be applied in relatives of subjects suffering from autopsy-negative SCD or unexplained cardiac arrest, to diagnose a heritable aetiology [25,26], which may be genetically transmissible. This is an important strategy for the early identification of asymptomatic relatives showing a positive test (genotype-positive), who may be predisposed to an increased risk of SCD. Indeed, the European Society of Human Genetics (ESHG) endorsed a guideline to perform post-mortem genetic testing, the so-called “molecular autopsy”, on blood or tissue samples from a suddenly deceased person [27]. Ackerman et al. first suggested that molecular autopsy could determine the aetiology of death in SCD when conventional autopsy resulted negative [28]. Subsequently, data in the literature showed that this approach may identify mutations in cardiomyopathy/channelopathy related genes, in about 30–40% of autopsy-negative sudden death cases, suggesting that an inheritable cardiac disorder was the responsible of SCD in these subjects [29,30,31,32,33,34,35]. Similarly, post-mortem genetic studies identified molecular alterations that can be causative or con-causative of SCD in athletes [36,37,38]. However, in recent years, several studies have addressed the issue of using genetic testing in athletes showing instrumental abnormalities (ECG and/or echocardiogram and/or cardiac magnetic resonance) or family history of cardiomyopathy or SCD, with the aim of early diagnosis of life-threatening cardiac genetic disorders [39,40,41,42,43,44,45,46,47,48,49,50].
On the basis of this evidence, in the review we discuss the genetic basis of SCD in athletes, and the effectiveness of the use of genetic testing in selected populations of athletes.

2. Genetic Basis of Inherited Cardiac Channelopathies

Channelopathies are a group of inherited primary electrophysiological disorders that display defects in ion channels and/or their regulatory proteins, without myocardial structural defects. LQTS, BrS, and CPVT are the most frequent cardiac channelopathies identified by genetic testing [51].

2.1. Long QT Syndrome (LQTS)

LQTS is a hereditary cardiac electrophysiological disorder characterized by the prolongation of QT interval in an ECG and propensity to tachyarrhythmias, including torsade de pointes, ventricular tachycardia and VF, that might result in SCD. The prevalence of LQTS in the general population has been estimated at 1:2500 [52,53]. LQTS can be suspected on a routine ECG if the corrected QT (QTc) interval is ≥480 ms, and the diagnosis is supported in the presence of additional clinical or ECG criteria, such as T-wave alternans, notched T-wave in at least three leads, low heart rate for age, previous torsade de pointes, syncope, family history of LQTS or SCD [54]. Patients with LQTS may be asymptomatic, or experience palpitations, lipothymia or syncopal episodes. SCD can represent the first manifestation of the disease. Arrhythmic events in LQT1 (KCNQ1 gene mutation) typically happen in situations of increased adrenergic tone (e.g., exercise, especially swimming), while in LQT2 (KCNH2 gene mutation) they typically happen as a result of strong emotions (especially sudden auditory stimuli), and in LQT3 (SCN5A) during sleep or rest [55]. Mutations associated with the LQTS phenotype have been found in at least 20 genes: AKAP9, ANK2, CACNA1C, CALM1, CALM2, CALM3, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNJ5, KCNQ1, KCNQ2, RYR2, SCN1B, SCN4B, SCN5A, SNTA1 and TRDN (genes and their function are described in Table 1). To date, about 800 pathogenic variations associated with LQTS have been reported in these genes (ClinVar database, available online: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/clinvar/ accessed on 26 August 2020), producing a global diagnostic sensitivity that can reach 85%. However, mutations in the KCNQ1, KCNH2, SCN5A genes, encoding the α subunit of the cardiac potassium channel Kv7.1, α subunit of the cardiac HERG potassium channel and α subunit of the cardiac sodium channel Nav1.5, respectively, are involved in about 75% of LQTS patients [56]. Therefore, the most recent evidence in diagnostic procedure suggested analysing KCNQ1, KCNH2, SCN5A genes only; CACNA1C, CALM1, CALM2, CALM3, KCNE1, KCNE2, KCNJ2, TRDN genes should be included in syndromic LQTS, or LQTS with atypical features, or in acquired LQTS (i.e., drug- or electrolyte-provoked LQTS) [57]. Of note, homozygous or compound heterozygous frameshift mutations in the TRDN gene have been associated to exercise-induced arrhythmias in early childhood [58,59]. Gene mutations in LQTS are typically inherited in an autosomal dominant pattern, except for KCNE1, KCNJ2, TRDN gene mutations, which are inherited in an autosomal recessive manner [57,60]. The proportion of a de novo pathogenic variant is low.

2.2. Brugada Syndrome (BrS)

Brugada syndrome is an inherited cardiac ion channel disease caused by mutations in trans-membrane ion channels, leading to an increased risk of cardiac arrhythmias, which may result in SCD. It is characterized by the typical coved-typed ST-segment elevation with a negative T wave in the right precordial leading to ECG without structural cardiac abnormalities [71]. Brugada syndrome shows a prevalence of 0.5 per 1000 in the general population, but it is more prevalent in South-East Asia, where a prevalence of 3.7 per 1000 is reported [72]. Different ECG patterns were described; however, only type 1, with coved ST elevation > 2 mm and negative T wave, is diagnostic for BrS (1). Type 2 (saddleback pattern) with ST elevation > 2 mm and positive T wave or type 3, which is characterized by either a saddleback or coved appearance with an ST elevation < 1 mm, could indicate the disease but requires further confirmation. A combination of the ECG changes and clinical criteria (such as syncope, family history of SCD, etc.) lead to a diagnosis of Brugada syndrome [73]. Actually, asymptomatic patients represent a majority (more than 60%) of newly diagnosed BrS patients (REF), while approximately one third presents with syncope. A minority of patient presents with cardiac arrest or SCD [74], which typically occur during sleep or at rest. More than 25 genes are actually known to be involved in BrS. However, mutations in the SCN5A gene are involved in about 20–25% of patients while other genes are rare (<5%) or very rare (<1%), (Table 1). Gene mutations in BrS are inherited with an autosomal dominant pattern; the exception is KCNE5-related Brugada syndrome (Locus Xq23), which is inherited in an X-linked manner. The proportion of de novo pathogenic variants is very low (estimated at 1%). Advances in identifying the genes involved in BrS have allowed the use of genetic testing in clinical practice. Molecular genetic testing includes the SCN5A exonic coding region; however, a multi-gene NGS panel including genes which encode for sodium, potassium, and calcium channels, or proteins associated with these channels (ABCC9, ANK3, CACNA1C, CACNA2D1, CACNB2, FGF12, GPD1L, HCN4, HEY2, KCND2, KCND3, KCNE3, KCNE5, KCNH2, KCNJ8, LRRC10, PKP2, RANGRF, SCN1B, SCN2B, SCN3B, SCN5A, SCN10A, SEMA3A, SLMAP, and TRPM4) may be used to identify a pathogenic variant (Table 1) [61,75,76]. About 500 pathogenic variations associated with BrS have been reported in these genes in the ClinVar database (ClinVar database, available online: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/clinvar/, accessed on 26 August 2020). The diagnostic sensitivity of the genetic test including all genes, to date, associated to BrS, is nearly 40% [77].

2.3. Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

CPVT is a primary electrical disease characterized by syncopal episodes occurring during exercise or acute emotion, in individuals without structural cardiac abnormalities. The estimated prevalence of CPVT is 1:5000/1:10,000 people [78]. The clinical manifestations of CPVT typically occur in the first decades of life and are triggered by physical or emotional stress. Patients with CPVT have a normal ECG and echocardiogram; therefore, an exercise stress test that elicits ventricular arrhythmias (bidirectional or polymorphic ventricular tachycardia) is necessary to establish the diagnosis [26]. Mutations in the RYR2 gene, encoding the Ryanodine receptor 2, are involved in about 60% of patients; mutations in the CASQ2 gene, encoding the Calsequestrin-2, are involved in about 5% of patients, while other genes (ANK2, CALM1, CALM2, CALM3, KCNJ2, and TRDN) are rare (<5%, Table 1) [79,80]. Therefore, the diagnostic sensitivity of genetic test is slightly higher than 60%, by searching mutations in these genes [81]. RYR2 gene mutations in CPVT are inherited in an autosomal dominant pattern, while CASQ2 gene mutations are inherited in an autosomal recessive manner. The proportion of a de novo pathogenic variant is particularly high (around 40%). About 200 pathogenic variations associated with CPVT have been reported in these genes (ClinVar database, available online: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/clinvar/, accessed on 26 August 2020).

3. Genetic Basis of Inherited Cardiomyopathies

Cardiomyopathies are a group of disorders in which the heart muscle is structurally and functionally abnormal in the absence of other diseases that could cause the observed myocardial abnormality [82]. Cardiomyopathies are classified into five different forms: hypertrophic (HCM), dilated (DCM), restrictive (RCM), arrhythmogenic (ACM) cardiomyopathies, and left ventricular non-compaction (LVNC). Globally, about 90 genes associated with hereditary cardiomyopathies have been identified [83].

3.1. Hypertrophic Cardiomyopathy (HCM)

HCM is a common inherited heart disease, affecting at least 1 in 500 people. It is the typical “sarcomeric” cardiomyopathy, most frequently related to mutations in genes encoding sarcomeric proteins, which induce overt structural damage or loss of function of the sarcomere (Figure 1). HCM is defined by the presence of increased left ventricular wall thickness (≥15 mm in adult index cases, or ≥13 mm in relatives of known affected patients, ≥2 standard deviations above the predicted population mean in children) that is not solely explained by abnormal loading condition [84]. Clinical manifestations are highly variable and usually related to the left ventricular outflow tract obstruction, mitral regurgitation, diastolic dysfunction, myocardial ischemia, and arrhythmias, and are represented by dyspnoea, chest pain and syncope [85]. Unfortunately, SCD may be the first manifestation of the disease. There are eight main genes associated, but the most common mutated ones are MYH7 and MYBPC3, encoding the sarcomeric proteins β-myosin heavy chain and cardiac myosin-binding protein C, respectively (Table 1) [86]. More than 450 unique pathogenic variations associated with HCM have been reported in MYBPC3 and MYH7 genes (ClinVar database, available online: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/clinvar/, accessed on 26 August 2020), while in 10% of HCM cases mutations in MYL2, MYL3, TPM1, TNNT2, TNNI3 and ACTC1 genes are reported [87] (Table 1). In addition to the eight main genes, other less commonly mutated genes associated with HCM have been identified: CSRP3, FHL1, PLN, ACTN2, CRYAB, FLNC, MYOZ2, MYH6, TNNC1, TRIM55, and TRIM63 (Table 1) [88]. The total diagnostic sensitivity of genetic test is about 65%. HCM has, generally, an autosomal dominant transmission, therefore it affects men and women in the same way; however, clinical diagnosis may be delayed because mutation penetrance is incomplete. In addition, epigenetic influences and environmental factors, such as sports, can influence the development of the pathology [89,90]. About 5% of individuals have compound/digenic heterozygosity [91]. These patients, generally, have a more severe phenotype with earlier onset and faster progression to the end-stage HCM [92].

3.2. Dilated Cardiomyopathy (DCM)

DCM is a myocardial disease characterized by ventricular dilation and depressed myocardial performance in the absence of hypertension, congenital, valvular, and ischemic heart disease. Men are more affected than women and DCM represents the most common cardiomyopathy in the world (40/100,000). It represents a heterogeneous disorder, which can be classified into genetic and non-genetic forms. The highest percentage of DCM (50–70%) is covered by genetic factors, while other acquired causes (thyroid pathologies, iron overload, exposure to cardiotoxic drugs, infections) are less frequent. In some cases, it can be asymptomatic, but if untreated it can lead to heart failure with reduced ejection fraction [93] with its classical presentation (dyspnoea, orthopnoea, leg swelling, shortness of breath, etc.). Inherited dilated cardiomyopathy appears to be as a monogenic trait with autosomal dominant, X-linked, autosomal-recessive, or matrilineal pattern of transmission. The molecular basis of DCM is very heterogeneous. To date, at least 50 different genes have been associated with the disease, with the main ones being: TTN, LMNA, MYH7, TNNT2, MYBPC3, SCN5A (Table 1). All these genes show an autosomal dominant inheritance [94]. TTN is the most frequently mutated gene with a prevalence of 12–25%, while LMNA appears to be the responsible gene in 10% of cases. A disease-causing mutation in ACTC1, MYBPC3, MYH7, MYL2, MYL3, TNNI3, TNNT2, and TPM1 can be identified in 5–10% of cases, and in SCN5A in 2–3% of cases. Mutations in the desmosomal genes (DSC2, DSG2, DSP, JUP, PKP2) are involved in 5% of patients, while other genes are rare (<5%) [95]. Genes coding for cytoskeleton proteins or dystroglycan-associated proteins can be rarely (<1%) mutated in DCM patients [62,95]. More than 200 pathogenic variations associated with DCM have been reported in the ClinVar database (ClinVar database, Available online: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/clinvar/, accessed on 26 August 2020), in the two major genes (TTN, LMNA).

3.3. Restrictive Cardiomyopathy (RCM)

Poorly distensible ventricular walls, which oppose diastolic filling, characterize RCM; either a single ventricle (more frequently the left) or both ones can be affected. RCM causes an increase in myocardial stiffness with small increases in ventricular volumes. This complicates the classification of the disease, as the same signs occur in HCM and DCM. The real prevalence of the disease is unknown. The main mutations associated with RCM affect the MYH7 and TNNI3 genes [89]. Thirty-seven pathogenic variations associated with RCM have been reported in these genes (ClinVar database, Available online: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/clinvar/, accessed on 26 August 2020). A recent study analysed, through NGS technology, 32 independent patients, who fulfilled the diagnostic criteria for idiopathic RCM and demonstrated that causative pathogenic variants can be identified in > 60% of cases in MYH7, DES, FLNC, MYBPC3, LMNA, TCAP, TNNI3, TNNT2, TPM1 and LAMP2 genes. Furthermore, considering the phenotypic overlap of HCM and RCM, the genetic test is fundamental to allow a differential diagnosis between these two pathologies [96].
Cardiac dysfunction may be part of the phenotype of mitochondrial disorders (MD). The most frequent cardiac manifestation of mitochondrial disorders is the HCM, generally associated with mutations in mitochondrial genes MTCO2, MTCO3, MTRNR1, MTRN2, MTTK, MTTL1 and nuclear genes SURF2, SCO2, MRPL3, MRPL44. More rarely, MD causes dilated cardiomyopathy, restrictive cardiomyopathy, or left ventricular non-compaction [62,97].

3.4. Arrhythmogenic Cardiomyopathy (ACM)

Arrhythmogenic cardiomyopathy represents one of the major causes of SCD in the young and athletes [98]. It is a rare disease (prevalence 1:2000–1:5000), generally transmitted in an autosomal dominant manner; however, autosomal recessive inheritance is sometimes reported. ACM is characterized by fibro-fatty replacement of the left and/or right ventricular myocardium, which predisposes patients to heart failure, ventricular arrhythmias and SCD. The main clinical features of ACM are palpitations, syncope, and cardiac arrest in teenagers and adults. Most mutations that cause ACM fall into the desmosomal genes: PKP2 (30–40%), DSG2 (3–20%), DSP (3–15%), and DSC2 (1–8%) (Table 1). For all these genes, the transmission is autosomal-dominant, except for DSC2, that shows both a dominant and recessive autosomal transmission pattern [95]. As for the desmosomal genes, over 300 unique pathogenetic variants associated with ACM are reported in ClinVar database (ClinVar database, available online: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/clinvar/, accessed on 26 August 2020). In addition, mutations in extra-desmosomal genes are reported, such as TTN, FLNC, LMNA, TMEM43, DES, PLN, genes typically associated with DCM, and SCN5A, more frequently associated with BrS or LQTS; nevertheless, molecular epidemiology studies showed a low frequency of mutations in these genes. These evidences highlight the genetic overlap of ACM with DCM and channelopathies [99]. Mutations in genes coding proteins involved in other types of cell-cell junctions have been recently described, such as CADH2 and CTTNA3, involved in the formation of adherent junctions, or TJP1 gene, which encodes zonula occludens-1 intercalated disk protein. However, the prevalence of these ACM form remains to be determined [100,101]. Therefore, the hypothesis that has been postulated is that ACM is not exclusively a desmosomal disease, but it more generally involves the intercalary discs. Interesting, up to 25% of ACM patients shows compound/digenic heterozygosity, which is related to a major risk of life-threatening arrhythmias and SCD [102].

3.5. Left Ventricular Non-Compaction (LVNC)

LVNC is a very rare cardiomyopathy, estimated to affect from 8 to 12 per 1 million individuals each year. It is characterized by increased left ventricular trabeculations, a thin normal compacted layer of myocardium, and inter-trabecular recesses communicating with the LV cavity. This cardiomyopathy carries a high risk of malignant arrhythmias, thromboembolic phenomenon and left ventricular dysfunction [103]. The genetic basis of the LVNC remains complex and, similarly to other cardiomyopathies, environmental factors and several modifying genes influence the phenotypic expression [104]. The main genes associated with LVNC are MYH7, MYBPC3, ACTC1, TNNT2, DTNA, LDB3, and LMNA, which are also associated with other cardiomyopathies [81]. In most cases, LVNC is transmitted as an autosomal dominant pattern and more than 100 pathogenetic variants in the genes described above are associated with LVNC (ClinVar database, Available online: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/clinvar/, accessed on 26 August 2020).

4. Diagnostic Yield of Genetic Testing in Athletes

We reviewed the literature data, searching publications regarding the use of genetic tests to diagnose cardiomyopathy/channelopathy in athlete(s) or young subjects practicing sports. The objective was to assess the clinical validity and utility of genetic tests in the diagnostic work-up of athletes referred to tertiary cardiological centres for suspicion of inherited cardiac disease, following the pre-participation screening programme, to early identify high-risk athletes harboring such conditions and provide appropriate advice regarding participation in regular exercise and competitive sport.

4.1. Evidence Acquisition: Database Searching, Study Eligibility and Inclusion/Exclusion Criteria

The search followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology [105], and covered the PubMed and Scopus databases up to 2020. The search term used was “genetic test/gene testing” combined with “athlete(s)”, “sport”, “cardiomyopathy/cardiomyopathies”, “channelopathy/channelopathies”.
Two authors (N.T. and B.L.) independently chose papers based on the titles and the abstracts, firstly. Then, full texts were analysed. Only English-language publications were considered. We also searched through the bibliographies of selected articles to ensure that no other relevant articles were missed; however, no papers were found by these means. A word file reporting the selected papers was developed and made available to all the co-authors.
To minimize risk of bias and applicability, to be included in the analysis, studies had to report and discuss ethnicity, sex and age of athletes, reasons for enrolment, exhaustive clinical and instrumental evaluation, familiarity with SCD, technology of genetic test. A genetic test was considered positive when it identified actionable variants, i.e., variants classified as pathogenic/likely pathogenic, according to the American College of medical genetics and genomics (ACMG) guidelines [106]. Case reports were included. Studies that did not disclose the clinical/instrumental/genetic investigative modality or presented incomplete data were not included. Papers that reported post-mortem genetic analysis were excluded, as we did not aim to identify the contribution of genetic background in athletes who had unfortunately died suddenly, but we aimed to verify the clinical validity and utility of genetic tests in the setting of athletes’ healthcare if they showed signs/symptoms attributable to a genetic heart disease.
Any issue encountered by an author when extracting the data was discussed collectively and a consensus was adopted to harmonize the extraction process.

4.2. Evidence Synthesis

Twelve publications, ranging from 2008 to 2020, were found, meeting the above-mentioned eligibility criteria, in principle. Seven papers depicted eight single case reports of athletes of Caucasian origin [39,40,41,42,43,44]. However, we excluded three among seven, because they did not report technologies used to perform genetic test and/or the specifications of the identified genetic variants [39,40,41]. The remaining are four case reports of white, asymptomatic, amateur athletes, who showed ECG anomalies during the pre-participation screening requiring a thorough cardiac evaluation in tertiary referral centres (Table 2) [24,42,43,44]. Of note, an athlete reported that two relatives died suddenly at a young age [44]. Genetic analyses, performed using Sanger sequencing and/or next-generation sequencing, confirmed the diagnostic suspicion suggested by anamnestic, clinical and instrumental data (i.e., BrS, HCM and ACM, Sick Sinus Syndrome, respectively). Furthermore, the positive genetic test in the athlete made it possible to extend the genetic analysis to relatives, allowing to identify other asymptomatic carriers who had been discouraged from practicing competitive sports.
Five studies carried out a genetic test on athlete populations, including white and black, elite and amateur athletes [45,46,47,48,49,50]. Among these, we excluded the study of Macarie et al. [45], as the authors performed the genetic test using Multiple Ligation Dependent Probe Amplification (MLPA), exclusively, and did not precisely report the mutations found in the athletes. The study of Sheikh et al. did not investigate the SCD familiarity. However, all authors agreed to include it in the review, as the other inclusion criteria are completely met (Table 2).
Kadota et al. conducted, in 2015, the first systematic screening of sarcomere gene mutations in a cohort of Japanese athletes (N: 102) showing ECG abnormalities or mild cardiomegaly in the chest X-ray examination. The selection criteria to enrolment were as described in Pelliccia et al. [107], i.e., ECG patterns that may mimic HCM or ACM, which can be responsible for SCD during physical activity. They found sarcomere gene mutations in five athletes (4.6%), indicating, for the first time, the potential utility of genetic testing in trained athletes to perform a definitive diagnosis of HCM in subjects with early ECG signs of left ventricular wall thickness (Table 2) [46].
Subsequently, Sheikh et al. (2018) analysed 100 consecutive asymptomatic young athletes (50 black and 50 white) showing T-wave inversion (TWI) at ECG and a normal echocardiogram. The comprehensive clinical/instrumental evaluation diagnosed a cardiomyopathy in 21 athletes (19 HCM, 1 LVNC, 1 Fabry disease; 30% among white athletes and 12% among black). Furthermore, using a NGS panel of 311 genes related to cardiomyopathies/channelopathies, a disease-causing variant was identified in 10 athletes: 6 HCM, 1 Fabry disease; 1 LVNC, 1 LQTS and a pathogenic polymorphism in the transthyretin gene, associated with wild-type transthyretin amyloidosis. Of note, the latter two mutations were found in athletes negative at clinical investigation. The diagnostic yield of genetic testing was one half compared to clinical evaluation: however, it contributed to additional diagnoses in 2.5% of athletes with TWI in the absence of a clear clinical phenotype (Table 2) [47].
In 2020, we found two papers related to the issue of clinical significance of genetic screening in athletes (Table 2) [48,50]. Cronin et al. conducted a three-year prospective study, during which they selected 10 white male athletes showing TWI on ECG and phenotypically normal after clinical/instrumental evaluation. Analysing a panel of 133 genes associated with hereditary cardiomyopathies and channelopathies, they identified only variants of uncertain significance (VUS) in half of the athletes; therefore, they concluded that T wave inversion with a normal phenotype might be a benign athletic condition, although studies on larger populations are needed [48]. The recent study of Limongelli et al. assessed the value of genetic testing in the diagnostic flow-chart of athletes [50]. They analysed 61 elite or amateur white athletes, selected due to high suspicion for underlying cardiac disease following the pre-participation screening programme. The selected athletes underwent clinical evaluation and genetic testing, using both Sanger sequencing and NGS panel of 138 genes associated to cardiomyopathies/channelopathies. A total of 23% of the selected population had a definitive diagnosis of inherited cardiomyopathy; of note the diagnostic yield of genetic testing vs. clinical evaluation was 13% vs. 10%. This study supported the use of genetic testing in athletes when a thorough clinical evaluation elicited strong suspicion of cardiac disease but did not lead to a certain diagnosis.

5. Discussion

SCD is a catastrophic event, which appears even more devastating when it affects the athlete, who in the collective imagination is the prototype of wellbeing and good health. It is a rare event, accounting for nearly 6% of the total SCDs both in agonist and amateur young athletes [108,109,110]. Primary SCD prevention, identifying athletes who are at increased risk of SCD but who have not had an event, is a very complex issue.
The correlation between the practice of physical activity, especially if strenuous and continuative, and the risk of sudden death, has been known since the end of the last century [19]. Therefore, both the American Heart Association (AHA) and ESC endorsed the pre-participation cardiovascular screening of athletes as a life-saving and cost-effective strategy in athletes, including symptom evaluation, family history, physical examination and, in the ESC guidelines, 12-lead ECG [111,112]. The inclusion of the ECG in the pre-participation screening enhances its sensitivity to the early detection of athletes with a structural or electrical cardiac disease, which commonly are associated with ECG abnormalities. It represents a non-expensive and largely available test, which has proven to be more sensitive compared to history and physical examination protocol [113]. ECG is abnormal in more than 80% of individuals with cardiomyopathies and channelopathies, which are responsible for a large part of SCD in young competitive athletes, and the ECG abnormalities identified may be diagnostic or suspect for inherited cardiac diseases, leading in the latter case to further instrumental investigations, such as echocardiography, cardiac magnetic resonance (CMR), ambulatory ECG monitoring, signal-average ECG, etc. For example, the presence of type I Brugada pattern is diagnostic for BrS or the presence of prolonged QTc in an appropriate clinical context is diagnostic of LQTS. On the contrary, the presence of concomitant inferior and lateral T-wave inversion, ST-segment depression or pathological Q waves in a young athlete is highly suspect, but not diagnostic for HCM [114], and requires further investigations.
Although a comprehensive clinical and instrumental evaluation, based on pre-participation screening and further additional instrumental investigations, can obtain a final diagnosis in a large portion of athletes, in some cases the differential diagnosis between myocardial disease and athlete’s heart is difficult. Therefore, the structural, functional and electrical remodeling of the athlete’s heart may lead to ECG, echocardiographic and CMR abnormalities, which may be difficult to differentiate from an inherited cardiac disease. In this subgroup of patients, genetic testing may be resolutive.
The effectiveness of genetic testing in the pre-participation screening programme has aroused great interest in the world of clinical molecular biology, given the growing evidence that phenotypically silent mutations related to inherited channelopathies and cardiomyopathies can represent a predisposing factor for the appearance of fatal arrhythmias triggered by physical activity [24]. Therefore, a correct and early diagnosis of inherited cardiac disease could reduce the risk of SCD, however, this goal is a real challenge in the world of cardiology and sports medicine, and requires an integrated approach between different disciplines, which increasingly includes knowledge of molecular cardiology.
This review first highlighted the great genetic heterogeneity and complexity that characterizes the molecular basis of inherited channelopathies and cardiomyopathies related to SCD. This complexity imposes the need to refer to experts in the field of molecular cardiology, who can use the most advanced sequencing methods, such as NGS, to sequence multiple genes simultaneously, in the effort to reach the maximum genetic yield [57,61,75,76,88,95,100,101]. Another difficult issue is the interpretation of genetic variants in the context of SCD. Distinguishing the genetic results of clinical utility from the variants of uncertain significance needs expert molecular and biological interpretation, which must be related to detailed clinical data. Sometimes, specific functional analyses may be required [105,115].
Our second aim was to review papers that used genetic testing to identify athletes at risk of developing a potential life-threatening cardiac disease, to verify the applicability of the genetic test in the healthcare of athletes, when the initial pre-participation screening highlights the presence of clear cardiomyopathy, or subtle evidence of clinical markers of inherited disease (including evaluation of family history of hereditary cardiac disorders or SCD).
To date, a limited number of papers have addressed this issue. Several papers reported a single case showing early expression and/or family history of cardiac disease. Genetic analysis, moved by a specific diagnostic suspicion, revealed the presence of a disease-causing variant, and the athletes were disqualified from further competitive sport due to the risk of future occurrence of ventricular arrhythmia.
In the last five years, there has been increasing interest in verifying the roles of genetic testing in the healthcare of athletes at the population level. Some papers applied the genetic test in the diagnostic flow-chart of cohorts of athletes targeted for the evidence of ECG anomalies with/without clinical symptoms. These studies unveiled that the percentage of genotype-positive athletes is significant and contributes as an integrative diagnostic instrument in athletes selected on the basis of a strong clinical suspicion for inherited cardiac disease [39,40,41,42,43,44,45,46,49,50]. Indeed, Cronin et al. demonstrated that, in a small cohort of athletes (N: 10), the evidence of TWI at ECG without a clinical phenotype was not related to a specific genetic background [48]. On the other hand, in the study conducted by Sheikh et al. in 100 athletes with TWI at ECG, the genetic yield was 10%, as 10 athletes revealed a clear disease-causing variant. Of note, eight athletes showed clear cardiac disorders on the basis of comprehensive clinical investigation; two were found mutated in the absence of a clinical phenotype. Therefore, the additional contribution of genetic test in the diagnostic flow-chart of athletes with TWI was 2.5%, in the absence of a clear clinical phenotype [47].
Kadota et al., for the first time, used genetic testing to distinguish hypertrophic cardiomyopathy from the athlete’s heart in 102 Japanese athletes showing features of hypertrophy at ECG or at the chest radiograph [46]. In presence of these specific clinical red flags, the genetic test, performed by sequencing of four sarcomeric genes only, was positive in 4.6% of cases. Finally, 61 athletes with high suspicion of underlying cardiac disease underwent a genetic test in the study of Limongelli et al. [50]. The genetic analyses on this strictly selected population of athletes led to a final genetic diagnosis in eight athletes (8/61, 13%) with clinical suspicion for inherited cardiac diseases. Notably, genetic testing confirmed the presence of cardiac disease in 75% of athletes showing >3 red flags at clinical evaluation. The yield of genetic test was reduced to 14.2% and 8.1% in the presence of two or one red flag(s), respectively. Furthermore, a positive genetic test allows performing family cascade screening, which can diagnose other asymptomatic carrier relatives, thus helping to avoid potential SCD in relatives [50].
In conclusion, the analysed papers, although still few in number, show that it is necessary to correctly select athletes eligible for genetic testing, on the basis of phenotypic feature, to obtain maximum clinical efficacy.

6. Conclusions

The identification of specific DNA mutation(s) in athletes showing an overt cardiac disease or a subtle evidence of a cardiac inherited disease or family history of hereditary cardiac disorders/sudden cardiac death is an important step in the integrated flow-chart to reach a definitive diagnosis of channelopathies and cardiomyopathies in these subjects at risk of SCD. This issue represents a real application of predictive medicine in the field of such a dramatic event that could occur during intense physical activity, as is sometimes read about or learned in sports-related clinical practice.
On the other hand, the advent of the NGS has provided an important tool in the molecular genetics of inherited cardiac diseases, providing a relatively inexpensive instrument with which to investigate a broad spectrum of genes involved in cardiomyopathy and ion channel disorders. However, this field is only starting to make substantial inroads.

Author Contributions

G.F. and C.M. conceived and designed the study. N.T., B.L., and O.S. performed the data collection. E.M. and M.C. reviewed the cardiological data. F.B., B.M., G.F., and C.M. analysed the data. F.B., B.M., G.F. and C.M. wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Research Projects of National Interest (PRIN) from the Italian Ministry of University and Research grant (20173ZWACS).

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

ACMArrhythmogenic cardiomyopathy
AHA/ACCAmerican Heart Association/American College of Cardiology
ARVCArrhythmogenic right ventricular cardiomyopathies
BRSBrugada syndrome
CMRCardiac Magnetic Resonance
CPVTCatecholaminergic polymorphic ventricular tachycardia
DCMDilated cardiomyopathy
ECGElectrocardiogram
ESCEuropean Society of Cardiology
ESHGEuropean Society of Human Genetics
HCMHypertrophic cardiomyopathy
LQTSLong QT syndrome
LVNCLeft ventricular non-compaction
MDMitochondrial disorders
MLPAMultiplex Ligation-Dependent Probe Amplification
NGSNext generation sequencing
NRNot Reported
NSVTNon-Sustained Ventricular Tachycardia
PRISMAPreferred Reporting Items for Systematic Reviews and Meta-Analyses
QTccorrected QT
RCMRestrictive cardiomyopathy
SCDSudden cardiac death
SDStandard Deviation
TWIT-wave inversion
VFVentricular fibrillation
VAVentricular arrhythmias
YYear

References

  1. Priori, S.G.; Blomstrom-Lundqvist, C.; Mazzanti, A.; Blom, N.; Borggrefe, M.; Camm, J.; Elliott, P.M.; Fitzsimons, D.; Hatala, R.; Hindricks, G.; et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur. Heart J. 2015, 36, 2793–2867. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Thiene, G. Sudden cardiac death in the young: A genetic destiny? Clin. Med. 2018, 18, s17–s23. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Nielsen, J.C.; Lin, Y.J.; de Oliveira Figueiredo, M.J.; Sepehri Shamloo, A.; Alfie, A.; Boveda, S.; Dagres, N.; Di Toro, D.; Eckhardt, L.L.; Ellenbogen, K.; et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: Use the right tool for the right outcome, in the right population. Europace 2020. [Google Scholar] [CrossRef]
  4. Friedlander, Y.; Siscovick, D.S.; Weinmann, S.; Austin, M.A.; Psaty, B.M.; Lemaitre, R.N.; Arbogast, P.; Raghunathan, T.E.; Cobb, L.A. Family history as a risk factor for primary cardiac arrest. Circulation 1998, 97, 155–160. [Google Scholar] [CrossRef]
  5. Dekker, L.R.; Bezzina, C.R.; Henriques, J.P.; Tanck, M.W.; Koch, K.T.; Alings, M.W.; Arnold, A.E.; de Boer, M.J.; Gorgels, A.P.; Michels, H.R.; et al. Familial sudden death is an important risk factor for primary ventricular fibrillation: A case-control study in acute myocardial infarction patients. Circulation 2006, 114, 1140–1145. [Google Scholar] [CrossRef] [Green Version]
  6. Bezzina, C.R.; Pazoki, R.; Bardai, A.; Marsman, R.F.; de Jong, J.; Blom, M.T.; Scicluna, B.P.; Jukema, J.W.; Bindraban, N.R.; Lichtner, P.; et al. Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. Nat. Genet. 2010, 42, 688–691. [Google Scholar] [CrossRef] [Green Version]
  7. Arking, D.E.; Junttila, M.J.; Goyette, P.; Huertas-Vazquez, A.; Eijgelsheim, M.; Blom, M.T.; Newton-Cheh, C.; Reinier, K.; Teodorescu, C.; Uy-Evanado, A.; et al. Identification of a sudden cardiac death susceptibility locus at 2q24.2 through genome-wide association in European ancestry individuals. PLoS Genet. 2011, 7, e1002158. [Google Scholar] [CrossRef]
  8. Al-Khatib, S.M.; Stevenson, W.G.; Ackerman, M.J.; Bryant, W.J.; Callans, D.J.; Curtis, A.B.; Deal, B.J.; Dickfeld, T.; Field, M.E.; Fonarow, G.C.; et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 2018, 72, e91–e220. [Google Scholar] [CrossRef]
  9. Gehi, A.K.; Duong, T.D.; Metz, L.D.; Gomes, J.A.; Mehta, D. Risk stratification of individuals with the Brugada electrocardiogram: A meta-analysis. J. Cardiovasc. Electrophysiol. 2006, 17, 577–583. [Google Scholar] [CrossRef]
  10. Priori, S.G.; Napolitano, C.; Gasparini, M.; Pappone, C.; Della Bella, P.; Giordano, U.; Bloise, R.; Giustetto, C.; De Nardis, R.; Grillo, M.; et al. Natural history of Brugada syndrome: Insights for risk stratification and management. Circulation 2002, 105, 1342–1347. [Google Scholar] [CrossRef] [Green Version]
  11. El-Sherif, N.; Turitto, G. Electrolyte disorders and arrhythmogenesis. Cardiol. J. 2011, 18, 233–245. [Google Scholar] [PubMed]
  12. Laslett, D.B.; Cooper, J.M.; Greenberg, R.M.; Yesenosky, G.A.; Basil, A.; Gangireddy, C.; Whitman, I.R. Electrolyte Abnormalities in Patients Presenting with Ventricular Arrhythmia (from the LYTE-VT Study). Am. J. Cardiol. 2020. [Google Scholar] [CrossRef] [PubMed]
  13. Afzal, M.R.; Savona, S.; Mohamed, O.; Mohamed-Osman, A.; Kalbfleisch, S.J. Hypertension and Arrhythmias. Heart Fail. Clin. 2019, 15, 543–550. [Google Scholar] [CrossRef]
  14. Solomon, R.J. Ventricular arrhythmias in patients with myocardial infarction and ischaemia. Relationship to serum potassium and magnesium. Drugs 1984, 28 (Suppl. 1), 66–76. [Google Scholar] [CrossRef] [PubMed]
  15. Glinge, C.; Engstrom, T.; Midgley, S.E.; Tanck, M.W.T.; Madsen, J.E.H.; Pedersen, F.; Ravn Jacobsen, M.; Lodder, E.M.; Al-Hussainy, N.R.; Kjaer Stampe, N.; et al. Seasonality of ventricular fibrillation at first myocardial infarction and association with viral exposure. PLoS ONE 2020, 15, e0226936. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Enriquez, A.; Frankel, D.S. Arrhythmogenic effects of energy drinks. J. Cardiovasc. Electrophysiol. 2017, 28, 711–717. [Google Scholar] [CrossRef]
  17. Maurin, O.; Lemoine, S.; Jost, D.; Lanoe, V.; Renard, A.; Travers, S.; The Paris Fire Brigade Cardiac Arrest Work Group; Lapostolle, F.; Tourtier, J.P. Maternal out-of-hospital cardiac arrest: A retrospective observational study. Resuscitation 2019, 135, 205–211. [Google Scholar] [CrossRef]
  18. Alexandre, J.; Moslehi, J.J.; Bersell, K.R.; Funck-Brentano, C.; Roden, D.M.; Salem, J.E. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Pharmacol. Ther. 2018, 189, 89–103. [Google Scholar] [CrossRef]
  19. Corrado, D.; Basso, C.; Rizzoli, G.; Schiavon, M.; Thiene, G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J. Am. Coll. Cardiol. 2003, 42, 1959–1963. [Google Scholar] [CrossRef]
  20. Schmied, C.; Borjesson, M. Sudden cardiac death in athletes. J. Intern. Med. 2014, 275, 93–103. [Google Scholar] [CrossRef]
  21. Bezzina, C.R.; Lahrouchi, N.; Priori, S.G. Genetics of sudden cardiac death. Circ. Res. 2015, 116, 1919–1936. [Google Scholar] [CrossRef] [PubMed]
  22. Girolami, F.; Frisso, G.; Benelli, M.; Crotti, L.; Iascone, M.; Mango, R.; Mazzaccara, C.; Pilichou, K.; Arbustini, E.; Tomberli, B.; et al. Contemporary genetic testing in inherited cardiac disease: Tools, ethical issues, and clinical applications. J Cardiovasc. Med. 2018, 19, 1–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Jagu, B.; Charpentier, F.; Toumaniantz, G. Identifying potential functional impact of mutations and polymorphisms: Linking heart failure, increased risk of arrhythmias and sudden cardiac death. Front Physiol. 2013, 4, 254. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Detta, N.; Frisso, G.; Limongelli, G.; Marzullo, M.; Calabro, R.; Salvatore, F. Genetic analysis in a family affected by sick sinus syndrome may reduce the sudden death risk in a young aspiring competitive athlete. Int. J. Cardiol. 2014, 170, e63–e65. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Kumar, S.; Peters, S.; Thompson, T.; Morgan, N.; Maccicoca, I.; Trainer, A.; Zentner, D.; Kalman, J.M.; Winship, I.; Vohra, J.K. Familial cardiological and targeted genetic evaluation: Low yield in sudden unexplained death and high yield in unexplained cardiac arrest syndromes. Heart Rhythm. 2013, 10, 1653–1660. [Google Scholar] [CrossRef]
  26. Monda, E.; Sarubbi, B.; Russo, M.G.; Caiazza, M.; Mazzaccara, C.; Magrelli, J.; Rubino, M.; Esposito, A.; Perna, A.; Passariello, A.; et al. Unexplained sudden cardiac arrest in children: Clinical and genetic characteristics of survivors. Eur. J. Prev. Cardiol. 2020. [Google Scholar] [CrossRef]
  27. Fellmann, F.; van El, C.G.; Charron, P.; Michaud, K.; Howard, H.C.; Boers, S.N.; Clarke, A.J.; Duguet, A.M.; Forzano, F.; Kauferstein, S.; et al. European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death. Eur. J. Hum. Genet. EJHG 2019, 27, 1763–1773. [Google Scholar] [CrossRef] [Green Version]
  28. Ackerman, M.J.; Tester, D.J.; Driscoll, D.J. Molecular autopsy of sudden unexplained death in the young. Am. J. Forensic Med. Pathol. 2001, 22, 105–111. [Google Scholar] [CrossRef]
  29. Tester, D.J.; Medeiros-Domingo, A.; Will, M.L.; Haglund, C.M.; Ackerman, M.J. Cardiac channel molecular autopsy: Insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. Mayo Clin. Proc. 2012, 87, 524–539. [Google Scholar] [CrossRef] [Green Version]
  30. Tester, D.J.; Spoon, D.B.; Valdivia, H.H.; Makielski, J.C.; Ackerman, M.J. Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: A molecular autopsy of 49 medical examiner/coroner’s cases. Mayo Clin. Proc. 2004, 79, 1380–1384. [Google Scholar] [CrossRef]
  31. Hellenthal, N.; Gaertner-Rommel, A.; Klauke, B.; Paluszkiewicz, L.; Stuhr, M.; Kerner, T.; Farr, M.; Puschel, K.; Milting, H. Molecular autopsy of sudden unexplained deaths reveals genetic predispositions for cardiac diseases among young forensic cases. Europace 2017, 19, 1881–1890. [Google Scholar] [CrossRef] [PubMed]
  32. Hertz, C.L.; Christiansen, S.L.; Ferrero-Miliani, L.; Dahl, M.; Weeke, P.E.; LuCamp; Ottesen, G.L.; Frank-Hansen, R.; Bundgaard, H.; Morling, N. Next-generation sequencing of 100 candidate genes in young victims of suspected sudden cardiac death with structural abnormalities of the heart. Int. J. Leg. Med. 2016, 130, 91–102. [Google Scholar] [CrossRef]
  33. Christiansen, S.L.; Hertz, C.L.; Ferrero-Miliani, L.; Dahl, M.; Weeke, P.E.; LuCamp; Ottesen, G.L.; Frank-Hansen, R.; Bundgaard, H.; Morling, N. Genetic investigation of 100 heart genes in sudden unexplained death victims in a forensic setting. Eur. J. Hum. Genet. EJHG 2016, 24, 1797–1802. [Google Scholar] [CrossRef] [PubMed]
  34. Nunn, L.M.; Lopes, L.R.; Syrris, P.; Murphy, C.; Plagnol, V.; Firman, E.; Dalageorgou, C.; Zorio, E.; Domingo, D.; Murday, V.; et al. Diagnostic yield of molecular autopsy in patients with sudden arrhythmic death syndrome using targeted exome sequencing. Europace 2016, 18, 888–896. [Google Scholar] [CrossRef] [PubMed]
  35. Semsarian, C.; Ingles, J.; Wilde, A.A. Sudden cardiac death in the young: The molecular autopsy and a practical approach to surviving relatives. Eur. Heart J. 2015, 36, 1290–1296. [Google Scholar] [CrossRef] [PubMed]
  36. Campuzano, O.; Sanchez-Molero, O.; Fernandez, A.; Mademont-Soler, I.; Coll, M.; Perez-Serra, A.; Mates, J.; Del Olmo, B.; Pico, F.; Nogue-Navarro, L.; et al. Sudden Arrhythmic Death During Exercise: A Post-Mortem Genetic Analysis. Sports Med. 2017, 47, 2101–2115. [Google Scholar] [CrossRef]
  37. Miles, C.; Finocchiaro, G.; Papadakis, M.; Gray, B.; Westaby, J.; Ensam, B.; Basu, J.; Parry-Williams, G.; Papatheodorou, E.; Paterson, C.; et al. Sudden Death and Left Ventricular Involvement in Arrhythmogenic Cardiomyopathy. Circulation 2019, 139, 1786–1797. [Google Scholar] [CrossRef]
  38. Morentin, B.; Suarez-Mier, M.P.; Monzo, A.; Molina, P.; Lucena, J.S. Sports-related sudden cardiac death due to myocardial diseases on a population from 1-35 years: A multicentre forensic study in Spain. Forensic Sci. Res. 2019, 4, 257–266. [Google Scholar] [CrossRef]
  39. Martin, M.; Reguero, J.J.; Castro, M.G.; Coto, E.; Hernandez, E.; Carro, A.; Calvo, D.; de la Tassa, C.M. Hypertrophic cardiomyopathy and athlete’s heart: A tale of two entities. Eur. J. Echocardiogr. 2009, 10, 151–153. [Google Scholar] [CrossRef]
  40. Richard, P.; Denjoy, I.; Fressart, V.; Wilson, M.G.; Carre, F.; Charron, P. Advising a cardiac disease gene positive yet phenotype negative or borderline abnormal athlete: Is sporting disqualification really necessary? Br. J. Sports Med. 2012, 46 (Suppl. 1), i59–i68. [Google Scholar] [CrossRef]
  41. Kebed, K.Y.; Bos, J.M.; Anavekar, N.S.; Mulvagh, S.L.; Ackerman, M.J.; Ommen, S.R. Hypertrophic Cardiomyopathy, Athlete’s Heart, or Both: A Case of Hypertrophic Cardiomyopathy Regression. Circ. Cardiovasc. Imaging 2015, 8, e003312. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. D’Argenio, V.; Esposito, M.V.; Nunziato, M.; De Simone, A.; Buono, P.; Salvatore, F.; Frisso, G. Molecular diagnosis of Brugada syndrome via next-generation sequencing of a multigene panel in a young athlete. Med. Sport 2018, 71, 27–34. [Google Scholar] [CrossRef]
  43. Mazzaccara, C.; Redi, A.; Lemme, E.; Pelliccia, A.; Salvatore, F.; Frisso, G. Impact of molecular diagnostics in an asymptomatic amateur athlete found to be affected by hypertrophic cardiomyopathy. Med. Sport 2018, 71, 405–412. [Google Scholar] [CrossRef]
  44. Limongelli, G.; Nunziato, M.; Mazzaccara, C.; Intrieri, M.; D’Argenio, V.; Esposito, M.V.; Monda, E.; Maggio, F.D.; Frisso, G.; Salvatore, F. Genotype-Phenotype Correlation: A Triple DNA Mutational Event in a Boy Entering Sport Conveys an Additional Pathogenicity Risk. Genes 2020, 11. [Google Scholar] [CrossRef] [PubMed]
  45. Macarie, C.; Stoian, I.; Dermengiu, D.; Barbarii, L.; Piser, I.T.; Chioncel, O.; Carp, A. The electrocardiographic abnormalities in highly trained athletes compared to the genetic study related to causes of unexpected sudden cardiac death. J. Med. Life 2009, 2, 361–372. [Google Scholar]
  46. Kadota, C.; Arimura, T.; Hayashi, T.; Naruse, T.K.; Kawai, S.; Kimura, A. Screening of sarcomere gene mutations in young athletes with abnormal findings in electrocardiography: Identification of a MYH7 mutation and MYBPC3 mutations. J. Hum. Genet. 2015, 60, 641–645. [Google Scholar] [CrossRef]
  47. Sheikh, N.; Papadakis, M.; Wilson, M.; Malhotra, A.; Adamuz, C.; Homfray, T.; Monserrat, L.; Behr, E.R.; Sharma, S. Diagnostic Yield of Genetic Testing in Young Athletes With T-Wave Inversion. Circulation 2018, 138, 1184–1194. [Google Scholar] [CrossRef]
  48. Cronin, H.; Crinion, D.; Kerins, D.; Fahy, G.; Vaughan, C.J. Inferolateral T wave inversion in athletes: Phenotype-genotype correlation. Ir. J. Med. Sci. 2020. [Google Scholar] [CrossRef]
  49. Zorzi, A.; Vessella, T.; De Lazzari, M.; Cipriani, A.; Menegon, V.; Sarto, G.; Spagnol, R.; Merlo, L.; Pegoraro, C.; Marra, M.P.; et al. Screening young athletes for diseases at risk of sudden cardiac death: Role of stress testing for ventricular arrhythmias. Eur. J. Prev. Cardiol. 2020, 27, 311–320. [Google Scholar] [CrossRef] [Green Version]
  50. Limongelli, G.; Nunziato, M.; D’Argenio, V.; Esposito, M.V.; Monda, E.; Mazzaccara, C.; Caiazza, M.; D’Aponte, A.; D’Andrea, A.; Bossone, E.; et al. Yield and clinical significance of genetic screening in elite and amateur athletes. Eur. J. Prev. Cardiol. 2020. [Google Scholar] [CrossRef]
  51. Skinner, J.R.; Winbo, A.; Abrams, D.; Vohra, J.; Wilde, A.A. Channelopathies That Lead to Sudden Cardiac Death: Clinical and Genetic Aspects. Heart Lung Circ. 2019, 28, 22–30. [Google Scholar] [CrossRef] [PubMed]
  52. Giudicessi, J.R.; Ackerman, M.J. Genotype- and phenotype-guided management of congenital long QT syndrome. Curr. Probl. Cardiol. 2013, 38, 417–455. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Lieve, K.V.; Wilde, A.A. Inherited ion channel diseases: A brief review. Europace 2015, 17 (Suppl. 2), ii1–ii6. [Google Scholar] [CrossRef]
  54. Schwartz, P.J.; Ackerman, M.J. The long QT syndrome: A transatlantic clinical approach to diagnosis and therapy. Eur. Heart J. 2013, 34, 3109–3116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Schwartz, P.J.; Priori, S.G.; Spazzolini, C.; Moss, A.J.; Vincent, G.M.; Napolitano, C.; Denjoy, I.; Guicheney, P.; Breithardt, G.; Keating, M.T.; et al. Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias. Circulation 2001, 103, 89–95. [Google Scholar] [CrossRef] [Green Version]
  56. Schwartz, P.J.; Ackerman, M.J.; George, A.L., Jr.; Wilde, A.A.M. Impact of genetics on the clinical management of channelopathies. J. Am. Coll. Cardiol. 2013, 62, 169–180. [Google Scholar] [CrossRef] [Green Version]
  57. Adler, A.; Novelli, V.; Amin, A.S.; Abiusi, E.; Care, M.; Nannenberg, E.A.; Feilotter, H.; Amenta, S.; Mazza, D.; Bikker, H.; et al. An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation 2020, 141, 418–428. [Google Scholar] [CrossRef]
  58. Altmann, H.M.; Tester, D.J.; Will, M.L.; Middha, S.; Evans, J.M.; Eckloff, B.W.; Ackerman, M.J. Homozygous/Compound Heterozygous Triadin Mutations Associated With Autosomal-Recessive Long-QT Syndrome and Pediatric Sudden Cardiac Arrest: Elucidation of the Triadin Knockout Syndrome. Circulation 2015, 131, 2051–2060. [Google Scholar] [CrossRef] [Green Version]
  59. Rooryck, C.; Kyndt, F.; Bozon, D.; Roux-Buisson, N.; Sacher, F.; Probst, V.; Thambo, J.B. New Family with Catecholaminergic Polymorphic Ventricular Tachycardia Linked to the Triadin Gene. J. Cardiovasc. Electrophysiol. 2015, 26, 1146–1150. [Google Scholar] [CrossRef]
  60. Takeda, I.; Takahashi, T.; Ueno, H.; Morino, H.; Ochi, K.; Nakamura, T.; Hosomi, N.; Kawakami, H.; Hashimoto, K.; Matsumoto, M. Autosomal recessive Andersen-Tawil syndrome with a novel mutation L94P in Kir2.1. Neurol. Clin. Neurosci. 2013, 1, 131–137. [Google Scholar] [CrossRef]
  61. Nakano, Y.; Shimizu, W. Genetics of long-QT syndrome. J. Hum. Genet. 2016, 61, 51–55. [Google Scholar] [CrossRef] [PubMed]
  62. Velcea, A.E.; Siliste, C.; Vinereanu, D. Catecholaminergic Polymorphic Ventricular Tachycardia—Looking to the Future. Maedica 2017, 12, 306–310. [Google Scholar] [PubMed]
  63. Tabish, A.M.; Azzimato, V.; Alexiadis, A.; Buyandelger, B.; Knoll, R. Genetic epidemiology of titin-truncating variants in the etiology of dilated cardiomyopathy. Biophys. Rev. 2017, 9, 207–223. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Hershberger, R.E.; Morales, A.; Siegfried, J.D. Clinical and genetic issues in dilated cardiomyopathy: A review for genetics professionals. Genet. Med. 2010, 12, 655–667. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. McNally, E.M.; Mestroni, L. Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. Circ. Res. 2017, 121, 731–748. [Google Scholar] [CrossRef]
  66. Maron, B.J.; Maron, M.S.; Semsarian, C. Genetics of hypertrophic cardiomyopathy after 20 years: Clinical perspectives. J. Am. Coll. Cardiol. 2012, 60, 705–715. [Google Scholar] [CrossRef] [Green Version]
  67. Kostareva, A.; Kiselev, A.; Gudkova, A.; Frishman, G.; Ruepp, A.; Frishman, D.; Smolina, N.; Tarnovskaya, S.; Nilsson, D.; Zlotina, A.; et al. Genetic Spectrum of Idiopathic Restrictive Cardiomyopathy Uncovered by Next-Generation Sequencing. PLoS ONE 2016, 11, e0163362. [Google Scholar] [CrossRef] [Green Version]
  68. Towbin, J.A.; Lorts, A.; Jefferies, J.L. Left ventricular non-compaction cardiomyopathy. Lancet 2015, 386, 813–825. [Google Scholar] [CrossRef]
  69. Detta, N.; Frisso, G.; Salvatore, F. The multi-faceted aspects of the complex cardiac Nav1.5 protein in membrane function and pathophysiology. Biochim. Biophys. Acta 2015, 1854, 1502–1509. [Google Scholar] [CrossRef] [Green Version]
  70. Vutthikraivit, W.; Rattanawong, P.; Putthapiban, P.; Sukhumthammarat, W.; Vathesatogkit, P.; Ngarmukos, T.; Thakkinstian, A. Worldwide Prevalence of Brugada Syndrome: A Systematic Review and Meta-Analysis. Acta Cardiol. Sin. 2018, 34, 267–277. [Google Scholar] [CrossRef]
  71. Antzelevitch, C.; Yan, G.X.; Ackerman, M.J.; Borggrefe, M.; Corrado, D.; Guo, J.; Gussak, I.; Hasdemir, C.; Horie, M.; Huikuri, H.; et al. J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. J. Arrhythmia 2016, 32, 315–339. [Google Scholar] [CrossRef] [PubMed]
  72. Probst, V.; Veltmann, C.; Eckardt, L.; Meregalli, P.G.; Gaita, F.; Tan, H.L.; Babuty, D.; Sacher, F.; Giustetto, C.; Schulze-Bahr, E.; et al. Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. Circulation 2010, 121, 635–643. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Brugada, J.; Campuzano, O.; Arbelo, E.; Sarquella-Brugada, G.; Brugada, R. Present Status of Brugada Syndrome: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2018, 72, 1046–1059. [Google Scholar] [CrossRef]
  74. Juang, J.J.; Horie, M. Genetics of Brugada syndrome. J. Arrhythmia 2016, 32, 418–425. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Sarquella-Brugada, G.; Campuzano, O.; Arbelo, E.; Brugada, J.; Brugada, R. Brugada syndrome: Clinical and genetic findings. Genet. Med. 2016, 18, 3–12. [Google Scholar] [CrossRef] [Green Version]
  76. Coppola, G.; Corrado, E.; Curnis, A.; Maglia, G.; Oriente, D.; Mignano, A.; Brugada, P. Update on Brugada Syndrome 2019. Curr. Probl. Cardiol. 2019, 100454. [Google Scholar] [CrossRef]
  77. Perez-Riera, A.R.; Barbosa-Barros, R.; de Rezende Barbosa, M.P.C.; Daminello-Raimundo, R.; de Lucca, A.A., Jr.; de Abreu, L.C. Catecholaminergic polymorphic ventricular tachycardia, an update. Ann. Noninvasive Electrocardiol. 2018, 23, e12512. [Google Scholar] [CrossRef]
  78. Roston, T.M.; Yuchi, Z.; Kannankeril, P.J.; Hathaway, J.; Vinocur, J.M.; Etheridge, S.P.; Potts, J.E.; Maginot, K.R.; Salerno, J.C.; Cohen, M.I.; et al. The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: Findings from an international multicentre registry. Europace 2018, 20, 541–547. [Google Scholar] [CrossRef]
  79. Sumitomo, N. Current topics in catecholaminergic polymorphic ventricular tachycardia. J. Arrhythmia 2016, 32, 344–351. [Google Scholar] [CrossRef] [Green Version]
  80. Wleklinski, M.J.; Kannankeril, P.J.; Knollmann, B.C. Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia. J. Physiol. 2020. [Google Scholar] [CrossRef]
  81. Schaufelberger, M. Cardiomyopathy and pregnancy. Heart 2019, 105, 1543–1551. [Google Scholar] [CrossRef] [PubMed]
  82. Lu, C.; Wu, W.; Liu, F.; Yang, K.; Li, J.; Liu, Y.; Wang, R.; Si, N.; Gao, P.; Zhang, S.; et al. Molecular analysis of inherited cardiomyopathy using next generation semiconductor sequencing technologies. J. Transl. Med. 2018, 16, 241. [Google Scholar] [CrossRef] [PubMed]
  83. Elliott, P.M.; Anastasakis, A.; Borger, M.A.; Borggrefe, M.; Cecchi, F.; Charron, P.; Hagege, A.A.; Lafont, A.; Limongelli, G.; Mahrholdt, H.; et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 2014, 35, 2733–2779. [Google Scholar] [CrossRef] [PubMed]
  84. Diez-Lopez, C.; Salazar-Mendiguchia, J. Clinical presentations of hypertrophic cardiomyopathy and implications for therapy. Glob. Cardiol. Sci. Pract. 2018, 2018, 19. [Google Scholar] [CrossRef] [Green Version]
  85. Limongelli, G.; Monda, E.; Tramonte, S.; Gragnano, F.; Masarone, D.; Frisso, G.; Esposito, A.; Gravino, R.; Ammendola, E.; Salerno, G.; et al. Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. Int. J. Cardiol. 2020, 299, 186–191. [Google Scholar] [CrossRef]
  86. Yotti, R.; Seidman, C.E.; Seidman, J.G. Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies. Annu. Rev. Genom. Hum. Genet. 2019, 20, 129–153. [Google Scholar] [CrossRef]
  87. Walsh, R.; Buchan, R.; Wilk, A.; John, S.; Felkin, L.E.; Thomson, K.L.; Chiaw, T.H.; Loong, C.C.W.; Pua, C.J.; Raphael, C.; et al. Defining the genetic architecture of hypertrophic cardiomyopathy: Re-evaluating the role of non-sarcomeric genes. Eur. Heart J. 2017, 38, 3461–3468. [Google Scholar] [CrossRef]
  88. Burke, M.A.; Cook, S.A.; Seidman, J.G.; Seidman, C.E. Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy. J. Am. Coll. Cardiol. 2016, 68, 2871–2886. [Google Scholar] [CrossRef]
  89. Esposito, A.; Monda, E.; Gragnano, F.; Simone, F.; Cesaro, A.; Natale, F.; Concilio, C.; Moscarella, E.; Caiazza, M.; Pazzanese, V.; et al. Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism. Eur. J. Prev. Cardiol. 2019. [Google Scholar] [CrossRef]
  90. Ingles, J.; Doolan, A.; Chiu, C.; Seidman, J.; Seidman, C.; Semsarian, C. Compound and double mutations in patients with hypertrophic cardiomyopathy: Implications for genetic testing and counselling. J. Med. Genet. 2005, 42, e59. [Google Scholar] [CrossRef] [Green Version]
  91. Biagini, E.; Olivotto, I.; Iascone, M.; Parodi, M.I.; Girolami, F.; Frisso, G.; Autore, C.; Limongelli, G.; Cecconi, M.; Maron, B.J.; et al. Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. Am. J. Cardiol. 2014, 114, 769–776. [Google Scholar] [CrossRef] [PubMed]
  92. Mazzaccara, C.; Limongelli, G.; Petretta, M.; Vastarella, R.; Pacileo, G.; Bonaduce, D.; Salvatore, F.; Frisso, G. A common polymorphism in the SCN5A gene is associated with dilated cardiomyopathy. J. Cardiovasc. Med. 2018, 19, 344–350. [Google Scholar] [CrossRef] [PubMed]
  93. Pinto, Y.M.; Elliott, P.M.; Arbustini, E.; Adler, Y.; Anastasakis, A.; Bohm, M.; Duboc, D.; Gimeno, J.; de Groote, P.; Imazio, M.; et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases. Eur. Heart J. 2016, 37, 1850–1858. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Mazzaccara, C.; Mirra, B.; Barretta, F.; Lombardo, B.; Scudiero, O.; Frisso, G. Sudden cardiac death in young athletes: Literature review of molecular basis. Cardiogenetics 2020, 10. [Google Scholar] [CrossRef] [Green Version]
  95. Gallego-Delgado, M.; Delgado, J.F.; Brossa-Loidi, V.; Palomo, J.; Marzoa-Rivas, R.; Perez-Villa, F.; Salazar-Mendiguchia, J.; Ruiz-Cano, M.J.; Gonzalez-Lopez, E.; Padron-Barthe, L.; et al. Idiopathic Restrictive Cardiomyopathy Is Primarily a Genetic Disease. J. Am. Coll. Cardiol. 2016, 67, 3021–3023. [Google Scholar] [CrossRef]
  96. Bates, M.G.; Bourke, J.P.; Giordano, C.; d’Amati, G.; Turnbull, D.M.; Taylor, R.W. Cardiac involvement in mitochondrial DNA disease: Clinical spectrum, diagnosis, and management. Eur. Heart J. 2012, 33, 3023–3033. [Google Scholar] [CrossRef] [Green Version]
  97. Pilichou, K.; Thiene, G.; Bauce, B.; Rigato, I.; Lazzarini, E.; Migliore, F.; Marra, M.P.; Rizzo, S.; Zorzi, A.; Daliento, L.; et al. Arrhythmogenic cardiomyopathy. Orphanet J. Rare Dis. 2016, 11. [Google Scholar] [CrossRef]
  98. Hoorntje, E.T.; Te Rijdt, W.P.; James, C.A.; Pilichou, K.; Basso, C.; Judge, D.P.; Bezzina, C.R.; van Tintelen, J.P. Arrhythmogenic cardiomyopathy: Pathology, genetics, and concepts in pathogenesis. Cardiovasc. Res. 2017, 113, 1521–1531. [Google Scholar] [CrossRef]
  99. Turkowski, K.L.; Tester, D.J.; Bos, J.M.; Haugaa, K.H.; Ackerman, M.J. Whole exome sequencing with genomic triangulation implicates CDH2-encoded N-cadherin as a novel pathogenic substrate for arrhythmogenic cardiomyopathy. Congenit. Heart Dis. 2017, 12, 226–235. [Google Scholar] [CrossRef]
  100. Poloni, G.; Calore, M.; Rigato, I.; Marras, E.; Minervini, G.; Mazzotti, E.; Lorenzon, A.; Li Mura, I.E.A.; Telatin, A.; Zara, I.; et al. A targeted next-generation gene panel reveals a novel heterozygous nonsense variant in the TP63 gene in patients with arrhythmogenic cardiomyopathy. Heart Rhythm. 2019, 16, 773–780. [Google Scholar] [CrossRef]
  101. Rigato, I.; Bauce, B.; Rampazzo, A.; Zorzi, A.; Pilichou, K.; Mazzotti, E.; Migliore, F.; Marra, M.P.; Lorenzon, A.; De Bortoli, M.; et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ. Cardiovasc. Genet. 2013, 6, 533–542. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  102. Ikeda, U.; Minamisawa, M.; Koyama, J. Isolated left ventricular non-compaction cardiomyopathy in adults. J. Cardiol. 2015, 65, 91–97. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  103. Arbustini, E.; Weidemann, F.; Hall, J.L. Left ventricular noncompaction: A distinct cardiomyopathy or a trait shared by different cardiac diseases? J. Am. Coll. Cardiol. 2014, 64, 1840–1850. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Hutton, B.; Salanti, G.; Caldwell, D.M.; Chaimani, A.; Schmid, C.H.; Cameron, C.; Ioannidis, J.P.; Straus, S.; Thorlund, K.; Jansen, J.P.; et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann. Intern. Med. 2015, 162, 777–784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  105. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [Google Scholar] [CrossRef]
  106. Pelliccia, A.; Maron, B.J.; Culasso, F.; Di Paolo, F.M.; Spataro, A.; Biffi, A.; Caselli, G.; Piovano, P. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation 2000, 102, 278–284. [Google Scholar] [CrossRef] [Green Version]
  107. Berdowski, J.; de Beus, M.F.; Blom, M.; Bardai, A.; Bots, M.L.; Doevendans, P.A.; Grobbee, D.E.; Tan, H.L.; Tijssen, J.G.; Koster, R.W.; et al. Exercise-related out-of-hospital cardiac arrest in the general population: Incidence and prognosis. Eur. Heart J. 2013, 34, 3616–3623. [Google Scholar] [CrossRef] [Green Version]
  108. Maron, B.J.; Thompson, P.D.; Ackerman, M.J.; Balady, G.; Berger, S.; Cohen, D.; Dimeff, R.; Douglas, P.S.; Glover, D.W.; Hutter, A.M., Jr.; et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: A scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation. Circulation 2007, 115, 1643–1655. [Google Scholar] [CrossRef] [Green Version]
  109. Corrado, D.; Pelliccia, A.; Bjornstad, H.H.; Vanhees, L.; Biffi, A.; Borjesson, M.; Panhuyzen-Goedkoop, N.; Deligiannis, A.; Solberg, E.; Dugmore, D.; et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: Proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur. Heart J. 2005, 26, 516–524. [Google Scholar] [CrossRef] [Green Version]
  110. Lombardo, B.; Izzo, V.; Terracciano, D.; Ranieri, A.; Mazzaccara, C.; Fimiani, F.; Cesaro, A.; Gentile, L.; Leggiero, E.; Pero, R.; et al. Laboratory medicine: Health evaluation in elite athletes. Clin. Chem. Lab. Med. 2019. [Google Scholar] [CrossRef]
  111. Frisso, G.; Detta, N.; Coppola, P.; Mazzaccara, C.; Pricolo, M.R.; D’Onofrio, A.; Limongelli, G.; Calabro, R.; Salvatore, F. Functional Studies and In Silico Analyses to Evaluate Non-Coding Variants in Inherited Cardiomyopathies. Int. J. Mol. Sci. 2016, 17, 1883. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  112. Heidbuchel, H.; Prior, D.L.; La Gerche, A. Ventricular arrhythmias associated with long-term endurance sports: What is the evidence? Br. J. Sports Med. 2012, 46 (Suppl. 1), i44–i50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  113. Sheikh, N.; Papadakis, M.; Schnell, F.; Panoulas, V.; Malhotra, A.; Wilson, M.; Carre, F.; Sharma, S. Clinical Profile of Athletes With Hypertrophic Cardiomyopathy. Circ. Cardiovasc. Imaging 2015, 8, e003454. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  114. Pricolo, M.R.; Herrero-Galan, E.; Mazzaccara, C.; Losi, M.A.; Alegre-Cebollada, J.; Frisso, G. Protein Thermodynamic Destabilization in the Assessment of Pathogenicity of a Variant of Uncertain Significance in Cardiac Myosin Binding Protein C. J. Cardiovasc. Transl. Res. 2020. [Google Scholar] [CrossRef]
  115. Levine, B.D.; Baggish, A.L.; Kovacs, R.J.; Link, M.S.; Maron, M.S.; Mitchell, J.H. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 1: Classification of Sports: Dynamic, Static, and Impact: A Scientific Statement From the American Heart Association and American College of Cardiology. J. Am. Coll. Cardiol. 2015, 66, 2350–2355. [Google Scholar] [CrossRef] [Green Version]
Ijms 21 06682 g001 550
Figure 1. Cartoon of the cardiomyocyte components involved in the molecular mechanisms associated with sudden cardiac death (SCD). The figure illustrates the main ion channels (Kyr7.1, HERG, Cav1.2, Nav1.5, Ryr2) linked to channelopathies (long QT syndrome (LQTS), Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT)); sarcomere proteins associated to hypertrophic cardiomyopathy (HCM); proteins participating in the organization of desmosomes and adherents junctions, linked to arrhythmogenic cardiomyopathy (ACM); the cytoplasmic, mitochondrial, sarcoplasmic reticulum proteins and the proteins of the dystroglycan complex that are associated with the development of dilated cardiomyopathy (DCM).
Figure 1. Cartoon of the cardiomyocyte components involved in the molecular mechanisms associated with sudden cardiac death (SCD). The figure illustrates the main ion channels (Kyr7.1, HERG, Cav1.2, Nav1.5, Ryr2) linked to channelopathies (long QT syndrome (LQTS), Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT)); sarcomere proteins associated to hypertrophic cardiomyopathy (HCM); proteins participating in the organization of desmosomes and adherents junctions, linked to arrhythmogenic cardiomyopathy (ACM); the cytoplasmic, mitochondrial, sarcoplasmic reticulum proteins and the proteins of the dystroglycan complex that are associated with the development of dilated cardiomyopathy (DCM).
Ijms 21 06682 g001
Table
Table 1. Major and Minor Genes Associated to Inherited Channelopathies and Cardiomyopathies.
Table 1. Major and Minor Genes Associated to Inherited Channelopathies and Cardiomyopathies.
DISEASEGene OMIM IDGENETRANSCRIPT
ID		Length bpPROTEINPrevalenceREF.Inheritance
Brugada Syndrome (BrS)601439ABCC9ENST00000261200.88293ATP-Binding Cassette, Subfamily C, Member 94–5%[61]AD
600465ANK3ENST00000280772.717019Ankyrin 3 (G)<5%[62]AD
611875CACNA1CENST00000399655.613744α subunit α1C of the Cav1.2 calcium channel6–7%[61]AD
114204CACNA2D1ENST00000356860.87542δ subunit Cavα2δ1 of calcium channel<5%[61]AD
611876CACNB2ENST00000324631.136129β subunit Cavβ2b of calcium channel4–5%[61]AD
601513FGF12ENST00000445105.65406Fibroblast growth factor 12<5%[62]AD
611777GPD1LENST00000282541.103947Glycerol-3-phosphate dehydrogenase 1-like<5%[61]AD
613123HCN4ENST00000261917.46922Hyperpolarization-activated cyclic nucleotide-gated channel 4<5%[61]AD
604674HEY2ENST00000368364.42626Hairy/Enhancer of Split-related with YRPW motif 2<5%[61]AD
605410KCND2ENST00000331113.95830α subunit of the KV4.2 potassium channel<5%[62]AD
616399KCND3ENST00000369697.57396α subunit of the KV4.3 potassium channel<5%[61]AD
613119KCNE3ENST00000310128.83143β subunit MiRP2 of potassium channel<5%[61]AD
300328KCNE5ENST00000372101.31473Potassium channel, voltage-gated, ISK-related family, member 1-like<5%[61]XLD
152427KCNH2ENST00000262186.104292α subunit of the HERG potassium channel<5%[61] [61]AD
600935KCNJ8ENST00000240662.32274α subunit of the KIR6.1 potassium channel<5%[61]AD
610846LRRC10ENST00000361484.52344Leucine-rich repeat-containing protein 10<5%[62]AD
602861PKP2ENST00000070846.104241Plakophilin 2<5%[61]AD
607954RANGRFENST00000226105.11831RAN guanine nucleotide release factor<5%[61]AD
612838SCN1BENST00000262631.111666β subunit Navβ1 of sodium channel<5%[61]AD
601327SCN2BENST00000278947.64937β subunit Navβ2 of sodium channel<5%[61]AD
613120SCN3BENST00000392770.66061β subunit Navβ3 of sodium channel<5%[61]AD
601144SCN5AENST00000423572.78516α subunit of the Nav1.5 sodium channel20–25%[61]AD
604427SCN10AENST00000449082.36626α subunit of the Nav1.8 sodium channel2.5–5%[62]AD
603961SEMA3AENST00000265362.98113Semaphorin family protein<5%[62]AD
602701SLMAPENST00000659705.16240Sarcolemma-associated protein<5%[61]AD
606936TRPM4ENST00000252826.104058Calcium-activated non-selective ion channel8%[61]AD
Long QT Syndrome (LQT)604001AKAP9ENST00000356239.812476A-kinase anchor protein 9<5%[63]AD
106410ANK2ENST00000357077.914215Ankyrin 2 (B)<5%[63]AD
114205CACNA1CENST00000399655.613744α subunit α1C of the Cav1.2 calcium channel<5%[63]AD
114180CALM1ENST00000356978.94203Calmodulin 1<5%[63]AD
114182CALM2ENST00000272298.121210Calmodulin 2<5%[63]AD
114183CALM3ENST00000291295.142184Calmodulin 3<5%[62]AD
601253CAV3ENST00000343849.31422Caveolin 3<5%[63]AD
176261KCNE1ENST00000399286.33505Potassium voltage-gated channel subfamily E regulatory subunit 1<5%[63]AD/AR
603796KCNE2ENST00000290310.1051Potassium voltage-gated channel subfamily E regulatory subunit 2<5%[63]AD
152427KCNH2ENST00000262186.104292α subunit of the HERG potassium channel25–30%[63]AD
600681KCNJ2ENST00000243457.45391Potassium inwardly-rectifying channel, subfamily J, member 2<5%[62]AD/AR
600734KCNJ5ENST00000529694.66068Potassium inwardly-rectifying channel, subfamily J, member 5<5%[63]AD
607542KCNQ1ENST00000155840.123224Potassium voltage-gated channel subfamily KQT member 130–35%[63]AD/AR
602235KCNQ2ENST00000626839.29213Potassium voltage-gated channel subfamily Q member 2<5%[62]AD
180902RYR2ENST00000366574.716583Ryanodine Receptor 2<5%[62]AD
600235SCN1BENST00000262631.111666Sodium voltage-gated channel beta subunit 1<5%[62]AD
608256SCN4BENST00000324727.84484Sodium voltage-gated channel beta subunit 4<5%[63]AD
600163SCN5AENST00000423572.78516α subunit of the Nav1.5 sodium channel5–10%[63]AD
601017SNTA1ENST00000217381.32211α1-Syntrophin<5%[63]AD
603283TRDNENST00000334268.94627Triadin<5%[62]AR
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)106410ANK2ENST00000357077.914215Ankyrin 2 (B)<5%[64]AD
114180CALM1ENST00000356978.94203Calmodulin 1<5%[64]AD
114182CALM2ENST00000272298.121210Calmodulin 2<5%[64]AD
114183CALM3ENST00000291295.142184Calmodulin 3<5%[62]AD
114251CASQ2ENST00000261448.52674Calsequestrin 25%[64]AR
600681KCNJ2ENST00000243457.45391Potassium inwardly-rectifying channel, subfamily J, member 2<5%[64]AR
180902RYR2ENST00000366574.716583Ryanodine Receptor 260%[64]AD
603283TRDNENST00000334268.94627Triadin<5%[64]AR
Arrhythmogenic Cardiomyopathy (ACM)114020CDH2ENST00000269141.84016Cadherin 2—N-Cadherin<5%[62]AD
607667CTNNA3ENST00000433211.710696Catenin, alpha 3<5%[62]AD
125660DESENST00000373960.42243Desmin<5%[62]AD
125645DSC2ENST00000280904.1112331Desmocollin 21–8%[62]AD/AR
125671DSG2ENST00000261590.135697Desmoglein 23–20%[62]AD
125647DSPENST00000379802.89697Desmoplakin3–15%[62]AD
102565FLNCENST00000325888.129188Filamin C<5%[62]AD
173325JUPENST00000393931.83505Junction plakoglobin<5%[62]AD
150330LMNAENST00000368300.93178Lamin A/C<5%[62]AD
172405PLNENST00000357525.62989Phospholamban<5%[62]AR
602861PKP2ENST00000070846.104241Plakophilin 230–40%[62]AD
180902RYR2ENST00000366574.716583Ryanodine receptor 2<5%[62]AD
601144SCN5AENST00000423572.78516α subunit of the Nav1.5 sodium channel<5%[62]AD
190230TGFB3ENST00000238682.72522Transforming Growth Factor β 3<5%[62]AD
612048TMEM43ENST00000306077.53230Transmembrane protein 43<5%[62]AD
188840TTNENST00000589042.5109224Titin0–10%[62]AD
Dilated Cardiomyopathy (DCM)601439ABCC9ENST00000261200.88293ATP-Binding Cassette, Subfamily C, Member 9<5%[62]AD
602330ABLIM1ENST00000392955.77408Limatin (actin-binding LIM domain protein)<5%[62]AD
102540ACTC1ENST00000290378.61382Actin, alpha, cardiac muscle<5%[65,66,67]AD
102573ACTN2ENST00000546208.55103Alpha-actinin 2<5%[62]AD
606844ALMS1ENST00000613296.512848ALMS1 centrosome and basal body associated protein<5%[62]AR
609599ANKRD1ENST00000371697.31979Ankyrin repeat domain-containing protein 1<5%[62]AD
608662ANO5ENST00000324559.96742Anoctamin 5<5%[62]AR
603883BAG3ENST00000369085.82561BCL2-associated athanogene<5%[62]AD
611414CALR3ENST00000269881.81263Calreticulin 3<5%[62]AD
114251CASQ2ENST00000261448.52674Calsequestrin 2<5%[62]AD
601253CAV3ENST00000343849.31422Caveolin 3<5%[62]AD
123590CRYABENST00000533475.61117Alpha B crystallin<5%[62]AD
600824CSRP3ENST00000533783.21457Cysteine- and glycine-rich protein 3<5%[62]AD
600435CTF1ENST00000279804.21664Cardiotrophin 1<5%[62]AD
128239DAG1ENST00000545947.55829Dystroglycan, alpha<5%[62]AR
125660DESENST00000373960.42243Desmin<5%[62]AD
300377DMDENST00000357033.813956Dystrophin<5%[62]XLR
605377DMPKENST00000291270.92799Dystrophia myotonica protein kinase gene<5%[62]AD
610746DOLKENST00000372586.42074Dolichol Kinase<5%[62]AR
125645DSC2ENST00000251081.812377Desmocollin 2<5%[62]AD
125671DSG2ENST00000261590.135697Desmoglein 2<5%[62]AD
125647DSPENST00000379802.89697Desmoplakin<5%[62]AD
601239DTNAENST00000283365.136522Dystrobrevin, alpha<5%[62]AD/AR
300384EMDENST00000369842.91281Emerin<5%[62]XLR
603550EYA4ENST00000355286.125701Eyes absent 4<5%[62]AD
300163FHL1ENST00000370683.62286Four-and—a-half LIM domains 1<5%[62]XLD/XLR
602633FHL2ENST00000409177.64881Four-and—a-half LIM domains 2<5%[62]AD
102565FLNCENST00000325888.129188Filamin C<5%[62]AD
614518GATAD1ENST00000287957.54571GATA Zinc Finger Domain Containing Protein 1<5%[62]AD
300644GLAENST00000218516.41318Galactosidase, alpha<5%[62]XLR
602366ILKENST00000299421.91759Integrin-linked kinase<5%[62]AD
173325JUPENST00000393931.83505Junction plakoglobin<5%[62]AD
156225LAMA2ENST00000421865.29640Laminin Alpha, 2<5%[62]AR
600133LAMA4ENST00000230538.127228Laminin Alpha, 4<5%[62]AD
309060LAMP2ENST00000200639.96535Lysosome-associated membrane protein 2<5%[62]XLR
605906LDB3ENST00000429277.65436LIM domain-binding 3<5%[62]AD
150330LMNAENST00000368300.93178Lamin A/C10%[62]AD
600958MYBPC3ENST00000545968.64217Myosin-binding protein C, cardiac<5%[65,66,67]AD
160710MYH6ENST00000405093.85945Alpha-myosin heavy chain 6<5%[62]AD
160760MYH7ENST00000355349.46027Myosin, heavy chain 7, cardiac muscle, beta<5%[65,66,67]AD
160781MYL2ENST00000228841.15783Myosin light chain 2<5%[65,66,67]AD
160790MYL3ENST00000292327.6885Myosin light chain 3<5%[65,66,67]AD/AR
605603MYOZ1ENST00000359322.51300Myozenin 1<5%[62]AD/AR
605602MYOZ2ENST00000307128.62549Myozenin 2<5%[62]AD
608517MYPNENST00000613327.46116Myopalladin<5%[62]AD
605491NEBLENST00000377122.89216Nebulette<5%[62]AD
613121NEXNENST00000330010.123195Nexilin<5%[62]AD
600584NKX2-5ENST00000329198.51558NK2 homeobox 5; cardiac specific homeobox 1<5%[62]AD
605900PDLIM1ENST00000329399.71431C-terminal LIM domain protein 1<5%[62]AD
605889PDLIM3ENST00000284767.122802PDZ and LIM domain protein 3<5%[62]AD
603422PDLIM4ENST00000253754.82257PDZ and LIM domain protein 4<5%[62]AD
602861PKP2ENST00000070846.104241Plakophilin 2<5%[62]AD
172405PLNENST00000357525.62989Phospholamban<5%[62]AR
605557PRDM16ENST00000270722.108698PR domain containing 16<5%[62]AD
602743PRKAG2ENST00000287878.93279Protein Kinase, AMP-Activated, Non-Catalytic, Gamma 2<5%[62]AD
104311PSEN1ENST00000324501.106018Presenilin 1<5%[62]AD
600759PSEN2ENST00000366783.82249Presenilin 2<5%[62]AD
176876PTPN11ENST00000351677.76073Protein-Tyrosine Phosphatase, Non-Receptor Type, 11<5%[62]AD
613171RBM20ENST00000369519.47293RNA-binding motif protein 201–5%[62]AD
609591RIT1ENST00000368323.83390RIC-like protein without CAAX motif 1<5%[62]AD
180902RYR2ENST00000366574.716583Ryanodine Receptor 2<5%[62]AD
601144SCN5AENST00000423572.78516α subunit of the Nav1.5 sodium channel<5%[62]AD
601411SGCDENST00000435422.79755Delta-sarcoglycan<5%[62]AD
603377SLC22A5ENST00000245407.83277Solute Carrier Family 22 (Organic Cation Transporter), Member 5<5%[62]AR
601017SNTA1ENST00000217381.32211α1-Syntrophin<5%[62]AD
182530SOS1ENST00000402219.78318SOS Ras/Rac guanine nucleotide exchange factor 1<5%[62]AD
607723SUN1ENST00000401592.64010SAD1 and UNC84 domain-containing protein 1<5%[62]AD
613569SUN2ENST00000405510.54055SAD1 and UNC84 domain-containing protein 2<5%[62]AD
608441SYNE1ENST00000367255.1027708Nesprin 1, Synaptic nuclear envelop protein 1<5%[62]AD
608442SYNE2ENST00000358025.721842Nesprin 2, Synaptic nuclear envelop protein 2<5%[62]AD
300394TAZENST00000601016.61906Tafazzin<5%[62]XLR
601620TBX5ENST00000405440.73733T-box 5<5%[62]AD
604488TCAPENST00000309889.3960Titin-cap; telethonin<5%[62]AD/AR
603306TCF21ENST00000367882.51280Transcription factor 21, epicardin<5%[62]AD
190230TGFB3ENST00000238682.72522Transforming Growth Factor β 3<5%[62]AD
612048TMEM43ENST00000306077.53230Transmembrane protein 43<5%[62]AD
188380TMPOENST00000556029.54242Thymopoietin<5%[62]AD
191040TNNC1ENST00000232975.8687Cardiac troponin C<5%[62]AD
191044TNNI3ENST00000344887.10843Cardiac troponin I3<5%[65,66,67]AD
191045TNNT2ENST00000656932.11165Cardiac troponin T2<5%[65,66,67]AD
191010TPM1ENST00000403994.91217Tropomyosin 1<5%[65,66,67]AD
188840TTNENST00000589042.5109224Titin12–25%[65,66,67]AD
176300TTRENST00000237014.8616Transthyretin<5%[62]AD
193065VCLENST00000211998.105497Vinculin<5%[62]AD
Hypertrophic Cardiomyopathy (HCM)102540ACTC1ENST00000290378.61382Actin, alpha, cardiac muscle<5%[68]AD
102573ACTN2ENST00000546208.55103Alpha-actinin 2<5%[62]AD
603883BAG3ENST00000369085.82561BCL2-associated athanogene<5%[62]AD
611414CALR3ENST00000269881.81263Calreticulin 3<5%[62]AD
601253CAV3ENST00000343849.31422Caveolin 3<5%[62]AD
123590CRYABENST00000650687.2774Alpha B crystallin<5%[62]AD
600824CSRP3ENST00000265968.91283Cysteine- and glycine-rich protein 3<5%[62]AD
125660DESENST00000373960.42243Desmin<5%[62]AD
300163FHL1ENST00000370683.62286Four-and—a-half LIM domains 1<5%[62]XLD/XLR
602633FHL2ENST00000409177.64881Four-and—a-half LIM domains 2<5%[62]AD
102565FLNCENST00000325888.129188Filamin C<5%[62]AD
300644GLAENST00000218516.41318Galactosidase, alpha<5%[62]XLR
602366ILKENST00000299421.91759Integrin-linked kinase<5%[62]AD
605267JPH2ENST00000372980.49502Junctophilin 2<5%[62]AD
309060LAMP2ENST00000200639.96535Lysosome-associated membrane protein 2<5%[62]XLR
605906LDB3ENST00000429277.65436LIM domain-binding 3<5%[62]AD
600958MYBPC3ENST00000545968.64217Myosin-binding protein C, cardiac30–40%[62]AD
160710MYH6ENST00000405093.85945Alpha-myosin heavy chain 6<5%[62]AD
160760MYH7ENST00000355349.46027Myosin, heavy chain 7, cardiac muscle, beta20–30%[62]AD
609928MYH7BENST00000262873.126293Myosin Heavy Chain 7B<5%[62]AD
160781MYL2ENST00000228841.15783Myosin light chain 2<5%[62]AD
160790MYL3ENST00000292327.6885Myosin light chain 3<5%[62]AD/AR
606566MYLK2ENST00000375985.52799Myosin light chain kinase 2<5%[62]AD
605603MYOZ1ENST00000359322.51300Myozenin 1<5%[62]AD/AR
605602MYOZ2ENST00000307128.62549Myozenin 2<5%[62]AD
608517MYPNENST00000613327.46116Myopalladin<5%[62]AD
613121NEXNENST00000330010.123195Nexilin<5%[62]AD
605900PDLIM1ENST00000329399.71431C-terminal LIM domain protein 1<5%[62]AD
605889PDLIM3ENST00000284767.122802PDZ and LIM domain protein 3<5%[62]AD
603422PDLIM4ENST00000253754.82257PDZ and LIM domain protein 4<5%[62]AD
172405PLNENST00000357525.62989Phospholamban<5%[62]AD
602743PRKAG2ENST00000287878.93279Protein Kinase, AMP-Activated, Non-Catalytic, Gamma 2<5%[62]AD
176876PTPN11ENST00000351677.76073Protein-Tyrosine Phosphatase, Non-Receptor Type, 11<5%[62]AD
604488TCAPENST00000309889.3960Titin-cap; telethonin<5%[62]AD/AR
612418TMEM70ENST00000312184.62032Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2<5%[62]AR
191040TNNC1ENST00000232975.8687Cardiac troponin C<5%[68]AD
191044TNNI3ENST00000344887.10843Cardiac troponin I32–5%[68]AD
191045TNNT2ENST00000656932.11165Cardiac troponin T210–20%[68]AD
191010TPM1ENST00000403994.91217Tropomyosin 12–5%[68]AD
188840TTNENST00000589042.5109224Titin<5%[62]AD
176300TTRENST00000237014.8616Transthyretin<5%[62]AD
193065VCLENST00000211998.105497Vinculin<5%[62]AD
Restrictive cardiomyopathy (RCM)125660DESENST00000373960.42243Desmin<5%[69]AD
102565FLNCENST00000325888.129188Filamin C<5%[69]AD
309060LAMP2ENST00000200639.96535Lysosome-associated membrane protein 2<5%[69]XLR
150330LMNAENST00000368300.93178Lamin A/C<5%[69]AD
600958MYBPC3ENST00000545968.64217Myosin-binding protein C, cardiac<5%[69]AD
160760MYH7ENST00000355349.46027Myosin, heavy chain 7, cardiac muscle, beta<5%[69]AD
604488TCAPENST00000309889.3960Titin-cap; telethonin<5%[69]AD/AR
191044TNNI3ENST00000344887.10843Cardiac troponin I3<5%[69]AD
191045TNNT2ENST00000656932.11165Cardiac troponin T2<5%[69]AD
191010TPM1ENST00000403994.91217Tropomyosin 1<5%[69]AD
Left ventricular non-compaction (LVNC)102540ACTC1ENST00000290378.61382Actin, alpha, cardiac muscle<5%[70]AD
601239DTNAENST00000283365.136522Dystrobrevin, alpha<5%[70]AD/AR
605906LDB3ENST00000429277.65436LIM domain-binding 3<5%[70]AD
150330LMNAENST00000368300.93178Lamin A/C<5%[70]AD
600958MYBPC3ENST00000545968.64217Myosin-binding protein C, cardiac8%[70]AD
160760MYH7ENST00000355349.46027Myosin, heavy chain 7, cardiac muscle, beta13%[70]AD
191045TNNT2ENST00000656932.11165Cardiac troponin T2<5%[70]AD
AD, Autosomic Dominant; AR, Autosomic Recessive; XLR, X-Linked Recessive; XLD, X-Linked Dominant.
Table
Table 2. Summary of the Literature Data Concerning the Use of Genetic Tests to Diagnose Cardiomyopathy/Channelopathy in Athlete(s).
Table 2. Summary of the Literature Data Concerning the Use of Genetic Tests to Diagnose Cardiomyopathy/Channelopathy in Athlete(s).
AuthorsAthletes (N)SexEthnicityAge Range (y)Age (y) or Mean Age
(y + SD)		Reason for Enrolment after Clinical EvaluationSCD FamiliarityTechnology of Genetic TestPositive Genetic Test (%)Reference
N. Detta et al., 201411 MWhiteNA12ECG: HR 50 bpm, with phases of sinus atrial blocksNoSanger (SCN5A, LMNA A/C,EMD, GJ5A, HCN4)100[24]
V. D’Argenio et al., 201811 MWhiteNA8ECG: BrS patternNoNGS Panel (75 genes)100[42]
C. Mazzaccara et al., 201811 MWhiteNA47HCMNoSanger (8 sarcomeric genes)100[43]
G. Limongelli et al., 202011 MWhiteNA12Putative ACMYesSanger (PKP2, DSP, DSG2, DSC2, RYR2, JUP).
NGS panel (138 genes)		100[44]
C. Kadota et al., 2015102NRNR18–28NRECG abnormalities; ECO abnormalities (N = 7)NoSanger: MYBPC3, TNNT2, TNNI3, MYH7 genes4.9[46]
N. Sheikh et al., 201810094 M
6 F		50 Black
50 White		14–3522.7 + 7.3 (Black) 25.1 + 7.1 (White)ECG: T-wave inversion.NRNGS panel (311 genes)Black: 6 White: 14[47]
H. Cronin et al., 20201010 MWhite18–5439ECG: deep T-wave inversion inferolaterally. All athletes were phenotypically normalNoNGS panel (133 genes)0[48]
G. Limongelli et al., 20206156 M
5 F		WhiteNR26 + 12.8Clinical suspicion for inherited cardiac diseaseYesNGS panel (138 genes)13[50]
Y, Year; SD, Standard Deviation; SCD, Sudden Cardiac Death; NA: Not Applicable; ECG, Electrocardiogram; HR: Heart Rate; bpm: beats per minute; BrS, Brugada Syndrome; NGS: Next Generation Sequencing; HCM: Hypertrophic Cardiomyopathy; ACM, Arrhthmogenic Cardiomyopathy; NR, Not Reported; ECO: Echocardiogram.

Share and Cite

MDPI and ACS Style

Barretta, F.; Mirra, B.; Monda, E.; Caiazza, M.; Lombardo, B.; Tinto, N.; Scudiero, O.; Frisso, G.; Mazzaccara, C. The Hidden Fragility in the Heart of the Athletes: A Review of Genetic Biomarkers. Int. J. Mol. Sci. 2020, 21, 6682. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21186682

AMA Style

Barretta F, Mirra B, Monda E, Caiazza M, Lombardo B, Tinto N, Scudiero O, Frisso G, Mazzaccara C. The Hidden Fragility in the Heart of the Athletes: A Review of Genetic Biomarkers. International Journal of Molecular Sciences. 2020; 21(18):6682. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21186682

Chicago/Turabian Style

Barretta, Ferdinando, Bruno Mirra, Emanuele Monda, Martina Caiazza, Barbara Lombardo, Nadia Tinto, Olga Scudiero, Giulia Frisso, and Cristina Mazzaccara. 2020. "The Hidden Fragility in the Heart of the Athletes: A Review of Genetic Biomarkers" International Journal of Molecular Sciences 21, no. 18: 6682. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21186682

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop